Avacopan

Tavneos (avacopan). Prescribing information. ChemoCentryx Inc; October 2021.

Beitz JG . NDA approval letter: Tavneos (avacopan) (NDA 214487). Food and Drug Administration. Published October 7, 2021. Accessed November 30, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/214487Orig1s000ltr.pdf

ChemoCentryx Inc. ChemoCentryx announces results of FDA advisory committee meeting on avacopan in ANCA-associated vasculitis [news release]. Published May 6, 2021. Accessed November 30, 2021. https://ir.chemocentryx.com/news-releases/news-release-details/chemocentryx-announces-results-fda-advisory-committee-meeting

ChemoCentryx. Evaluation of safety and efficacy of avacopan in subjects with moderate to severe hidradenitis suppurativa (AURORA). ClinicalTrials.gov identifier: NCT03852472. Updated September 29, 2020. Accessed November 30, 2021. https://clinicaltrials.gov/ct2/show/NCT03852472

ChemoCentryx. Controlled trial evaluating avacopan in C3 glomerulopathy (ACCOLADE). ClinicalTrials.gov identifier: NCT03301467. Updated November 24, 2021. Accessed November 30, 2021. https://clinicaltrials.gov/ct2/show/NCT03301467

Almaani S Fussner LA Brodsky S Meara AS Jayne D . ANCA-associated vasculitis: an update. J Clin Med. 2021;10(7):1446. doi:10.3390/jcm10071446

Food and Drug Administration. FDA briefing document: NDA 214487 (avacopan). Prepared for the Arthritis Advisory Committee Meeting; May 6, 2021. Accessed November 30, 2021. https://www.fda.gov/media/148176/download

Yates M Watts RA Bajema IM , et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133

Bekker P Dairaghi D Seitz L , et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS One. 2016;11(10):e0164646. doi:10.1371/journal.pone.0164646

Li XX Lee JD Massey NL , et al. Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function. Biochem Pharmacol. 2020;180:114156. doi:10.1016/j.bcp.2020.114156

Chung SA Langford CA Maz M , et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated Vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. doi:10.1002/art.41773

Jayne DRW Merkel PA Schall TJ Bekker P ; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. New Engl J Med. 2021;384(7):599-609. doi:10.1056/NEJMoa2023386

Merkel PA Jayne DR Wang C Hillson J Bekker P . Evaluation of the safety and efficacy of avacopan, a c5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc. 2020;9(4):e16664. doi:10.2196/16664

Jayne DRW Bruchfeld AN Harper L , et al.; CLEAR Study Group. Randomized trial of c5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756-2767. doi:10.1681/ASN.2016111179

Merkel PA Niles J Jimenez R , et al.; CLASSIC Investigators. Adjunctive treatment with avacopan, an oral c5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020;2(11):662-671. doi:10.1002/acr2.11185